Wellington Management Group LLP Sells 166,016 Shares of Sanofi (NASDAQ:SNY)

Wellington Management Group LLP trimmed its position in shares of Sanofi (NASDAQ:SNY) by 3.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,484,318 shares of the company’s stock after selling 166,016 shares during the period. Wellington Management Group LLP’s holdings in Sanofi were worth $216,279,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Raymond James Financial Inc. bought a new stake in shares of Sanofi during the 4th quarter worth $135,933,000. Boston Partners raised its stake in Sanofi by 86.4% during the fourth quarter. Boston Partners now owns 5,396,531 shares of the company’s stock worth $260,607,000 after acquiring an additional 2,501,073 shares in the last quarter. Magnetar Financial LLC lifted its holdings in shares of Sanofi by 104.3% in the fourth quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company’s stock worth $161,103,000 after acquiring an additional 1,705,148 shares during the last quarter. DAVENPORT & Co LLC boosted its stake in shares of Sanofi by 40.7% in the 4th quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock valued at $110,715,000 after purchasing an additional 664,455 shares in the last quarter. Finally, Thrivent Financial for Lutherans grew its holdings in shares of Sanofi by 36.0% during the 4th quarter. Thrivent Financial for Lutherans now owns 1,943,761 shares of the company’s stock valued at $93,774,000 after purchasing an additional 514,542 shares during the last quarter. 14.04% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Finally, The Goldman Sachs Group assumed coverage on Sanofi in a research note on Friday, March 21st. They set a “neutral” rating and a $65.00 price target on the stock. Three research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $62.50.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $53.95 on Thursday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. Sanofi has a 52 week low of $45.22 and a 52 week high of $60.12. The firm has a market cap of $136.92 billion, a PE ratio of 21.67, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. The firm’s fifty day moving average is $55.33 and its 200-day moving average is $52.74.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Sell-side analysts predict that Sanofi will post 4.36 earnings per share for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.